Abstract | OBJECTIVE: METHODS: Twelve patients with migraine with aura were enrolled in an open-label study and treated with topiramate for 6 months. The dose of topiramate was increased weekly by 25 mg up to a daily dose of 100 mg after 4 weeks. RESULTS: In all 12 patients after 6 months of treatment, topiramate did not statistically influence aura frequency (P=.317) or duration (P=.480) compared with baseline. Mild to moderate side effects were observed, but they did not interfere with treatment. Consistent with previous observations, migraine frequency as well as headache intensity and duration improved statistically significantly. CONCLUSION:
|
Authors | Christian Lampl, Silvia Bonelli, Gerhard Ransmayr |
Journal | Headache
(Headache)
Vol. 44
Issue 2
Pg. 174-6
(Feb 2004)
ISSN: 0017-8748 [Print] United States |
PMID | 14756858
(Publication Type: Journal Article)
|
Chemical References |
- Anticonvulsants
- Topiramate
- Fructose
|
Topics |
- Adolescent
- Adult
- Anticonvulsants
(adverse effects, therapeutic use)
- Female
- Fructose
(adverse effects, analogs & derivatives, therapeutic use)
- Humans
- Longitudinal Studies
- Male
- Migraine with Aura
(prevention & control)
- Pilot Projects
- Topiramate
|